Results 111 to 120 of about 737 (141)

Antiviral Effectiveness, Clinical Outcomes, and Artificial Intelligence Imaging Analysis for Hospitalized COVID-19 Patients Receiving Antivirals. [PDF]

Influenza Other Respir Viruses
Gao Y, Dong Y, Bu Q, Gong Z, Wang W, Zhou Z, Gao Y, Liu L, Wu M, Zhang J, Liang L, Li H, Jiang M, Luo Z, Ma Y, Zhang X, Hu Z.   +16 more
europepmc   +1 more source

Editorial: Drug development for respiratory infectious diseases and related complications in other systems. [PDF]

Front Med (Lausanne)
Yu X, Wang Y, Oliva A, Xue M.
europepmc   +1 more source

Identification of lead inhibitors for 3CLpro of SARS-CoV-2 target using machine learning based virtual screening, ADMET analysis, molecular docking and molecular dynamics simulations. [PDF]

RSC Adv
Chhetri SP, Bhandari VS, Maharjan R, Lamichhane TR.   +3 more
europepmc   +1 more source

Nirmatrelvir/ritonavir reduced mortality in severe or critical COVID-19 patients: a multicenter retrospective cohort study. [PDF]

Front Med (Lausanne)
Zhao H, Meng W, Lv X, Si S, Wu S, Li J, Cai Z, Jin R, Yang L, Li C, Song L.   +10 more
europepmc   +1 more source

Development and validation of a nomogram to assess the occurrence of liver dysfunction in patients with COVID-19 pneumonia in the ICU. [PDF]

BMC Infect Dis
Wang Z, Zhao L, Xie K.
europepmc   +1 more source

Comparative Analysis of Viral Load Quantification Using Reverse Transcription Polymerase Chain Reaction and Digital Droplet Polymerase Chain Reaction. [PDF]

Int J Mol Sci
Gebe Abreu Cabral P, Bastos de Souza S, Ferraz Arruda R, Passos de Figueiredo Cabral S, Leone Evangelista Monteiro de Assis A, Porto Muniz Martins Y, Brazil Viana Junior A, Chang J, Lei P, Martins da Silva R.   +9 more
europepmc   +1 more source

Azvudine and nirmatrelvir–ritonavir in hospitalized patients with moderate‐to‐severe COVID‐19: Emulation of a randomized target trial [PDF]

Journal of Medical Virology, 2023
To examine the effectiveness of azvudine and nirmatrelvir-ritonavir in treating hospitalized patients with moderate-to-severe COVID-19. We emulated a target trial with a multicenter retrospective cohort of hospitalized adults with moderate-to-severe ...
Yongzhao Zhou, Huohuo Zhang, Bi Ren
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Azvudine and mortality in patients with coronavirus disease 2019: A retrospective cohort study

International Immunopharmacology, 2023
Several studies have found that azvudine (FNC) can inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication both in vivo and in vitro. However, the effect of FNC on the risk of death in patients with coronavirus disease 2019 (COVID-19) is unclear.
Bin Liu, Mingjin Yang, Li Xu, Yishi Li, Jing Cai, Bo Xie, Kaican Zong, Shuliang Guo   +7 more
openaire   +2 more sources

Azvudine versus Paxlovid in COVID‐19: A systematic review and meta‐analysis

Reviews in Medical Virology
AbstractThis systematic review and meta‐analysis aimed to compare the effectiveness and safety of azvudine versus nirmatrelvir/ritonavir (Paxlovid) in treating coronavirus disease 2019 (COVID‐19). The researchers conducted searches on PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar until January 2024.
Bahman Amani
exaly   +3 more sources

A Nearly 20‐Year Journey to Success of Azvudine for Antiviral Therapy

Chinese Journal of Chemistry, 2023
Comprehensive SummaryModified nucleosides, particularly those with 4'‐modifications, are significant nucleosides used in antiviral treatments. The drug discovery campaign of Azvudine starts from 2′‐deoxynucleoside, followed by extensive modifications, such as introducing the 4’‐position substitutions, a 2’‐β‐fluoro atom, and changing the nucleobases ...
Bin Yu, Junbiao Chang
openaire   +1 more source